Accord Healthcare

What Accord Healthcare does

Accord Healthcare is a UK-headquartered, privately held pharmaceutical company operating as the international arm of India-based Intas Pharmaceuticals Ltd. Founded in Europe in 2008, it develops, manufactures, and distributes generic, biosimilar, and value-added specialty medicines across 80+ countries, with a network of 45+ European country affiliates plus regional operations in MENA, North America, Latin America, and APAC. Its therapeutic focus spans oncology and haematology (40+ treatments making it one of the largest chemotherapy suppliers in Europe), autoimmune diseases (liposomal and biosimilar platforms), central nervous system/mental health, plus cardiovascular, diabetes, pain management, and gastroenterology generics; it also operates Accord Animal Health for companion animal medicines.

The company is vertically integrated across six EU GMP-approved manufacturing plants and an EU packing site near Cambridge, UK, with proprietary capabilities in liposomal and pegylated formulation, biosimilar development, and patient-centric drug delivery devices. R&D is supported by 500+ in-house scientists and a pipeline of 15 additional oncology treatments slated for launch over the next five years. The recent acquisition of Prothya Biosolutions Belgium BV (October 2025) added plasma-derived medicinal products, expanding its specialty and biologics footprint.

Accord monetizes primarily through one-time product sales to hospitals, retail pharmacies, wholesalers, and national health systems, with pricing determined by competitive generics market dynamics and government reimbursement. Go-to-market is sales-led via direct country affiliates supplemented by exclusive distribution partners in smaller European markets, and it is increasingly adding specialty commercialization channels through partnerships such as the ImmunityBio ANKTIVA agreement across 30 European countries and MENA partnerships with Biopharma and Cigalah Healthcare. New Global CEO Paul Tredwell was appointed in September 2025 to lead the next phase of expansion.

Name

Accord Healthcare

Legal name

Accord Healthcare Ltd

Website

https://accord-healthcare.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Accord Healthcare is a UK-based global pharmaceutical company that develops, manufactures, and distributes generic, biosimilar, and specialty medicines across 80+ countries, serving hospitals, retail pharmacies, wholesalers, and national health systems through direct affiliates and distribution partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Generic pharmaceuticals
• Biosimilar medicines
• Oncology medicines
• Plasma-derived therapies
• Specialty pharmaceuticals

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices30 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Generic Medicines: Development, manufacturing and distribution of generic pharmaceutical products across Europe and global markets. Products span oncology, cardiology, neurology, psychiatry, diabetes, pain management and gastroenterology therapeutic areas. Revenue generated through sales to hospitals, retail pharmacies, wholesalers, and national health systems.
2. Biosimilars: Development and commercialization of biosimilar products. Accord has a growing biosimilar portfolio and pipeline targeting autoimmune diseases and other therapy areas. Revenue generated through product sales in European and global markets.
3. Specialty Brand Products: Added-value medicines under Speciality Brands covering Oncology and Haematology, Autoimmune, and Central Nervous System franchises. These products offer enhancements over standard medicines through improved delivery mechanisms and administration systems.
4. Plasma-Derived Medicinal Products: Following the acquisition of Prothya Biosolutions, Accord expanded into plasma-derived medicinal products (PDMPs) including blood plasma therapies, growing its presence in this specialized therapeutic area.
5. Animal Health: Accord Animal Health division provides high-quality veterinary medicines for companion animals, targeting vets with products focused on convenience, value, effectiveness, and innovation.

Go-to-market motion3 records

Distribution channels8 records

Marketing channels7 records

Core offering

Accord Healthcare develops, manufactures, and distributes generic, biosimilar, and added-value medicines across oncology, autoimmune, and central nervous system therapeutic areas. The company operates six EU GMP approved manufacturing plants plus an EU packing site near Cambridge, UK, producing a portfolio of more than 4,000 registered products sold in over 85 countries. Products are delivered to hospitals, retail pharmacies, wholesalers, and national health systems.

Product overview

Accord Healthcare is a multinational pharmaceutical company that develops, manufactures, and distributes generic medicines, biosimilars, and added-value speciality brand products across over 85 countries worldwide. The company operates a vertically integrated platform spanning the entire pharmaceutical value chain from API through manufacturing to distribution. Its core portfolio includes Oncology & Haematology (40+ treatments), Autoimmune (liposomal and biosimilar products), and Central Nervous System therapies, supported by Speciality Brand Products that offer enhanced delivery mechanisms. Following the 2025 acquisition of Prothya Biosolutions, the company expanded into plasma-derived medicinal products. Accord Healthcare also operates Accord Animal Health as a specialist division for companion animal medicines. The company maintains significant manufacturing capabilities with six EU GMP approved plants and an EU packing site near Cambridge, UK, supporting its position as one of Europe's largest generic and biosimilar pharmaceutical suppliers.

Differentiator

Problem solved

Functional benefit

Brands

• Accord Animal Health: Specialist division dedicated to improving the health and wellbeing of companion animals.
• Accord Oncology & Haematology
• Accord Autoimmune
• Accord Central Nervous System

Products and services

• Oncology & Haematology Portfolio Comprehensive portfolio of over 40 oncology and oncology-related treatments including chemotherapeutic agents and supportive care therapies, covering breast cancer, prostate cancer, haematological cancers, and cancer supportive care, with 15 additional treatments in development. Available to hospitals and oncology centers across Europe and globally.
• Autoimmune Portfolio Portfolio utilizing liposomal and biosimilar technology for autoimmune disease treatments across bone health and autoimmune therapy areas, with patient-centric self-administration devices and oral products designed for patient autonomy.
• Central Nervous System (CNS) Portfolio Portfolio of Mental Health and Addiction therapies focusing on psychiatric disorders and neurological conditions, with novel treatments targeting unmet needs beyond symptom control.
• Biosimilars Leading biosimilar portfolio in Europe with products across bone health and autoimmune therapy areas, with plans to launch additional biosimilars following the acquisition of Prothya Biosolutions.
• Generic Medicines Portfolio Broad range of hospital and pharmacy generic medicines spanning oncology, cardiology, neurology, psychiatry, diabetes, pain management, and gastroenterology, distributed across over 80 countries worldwide through more than 4,000 European product registrations.
• Accord Animal Health Specialist division dedicated to improving health and wellbeing of companion animals, providing veterinarians with high-quality, effective, convenient, and affordable veterinary medicines derived from Accord's human pharmaceutical expertise.
• Plasma-Derived Medicinal Products Plasma-derived medicinal products (PDMPs) including blood plasma therapies, operated through the acquired Prothya Biosolutions business primarily based in the Netherlands and Belgium, expanding access to plasma-derived medicines worldwide.

Quantifiable outcome

• Every 3 seconds a patient in Ireland takes an Accord medicine
• +4 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• ImmunityBiocoreChannel Partner/ Reseller/ Distributor · 19 February 2026Accord Healthcare partnered with ImmunityBio to commercialize ANKTIVA (nogapendekin alfa inbakicept) for BCG-unresponsive non-muscle invasive bladder cancer across 30 European countries. Accord deployed 85-100 sales, medical, and marketing professionals to drive the European launch covering the UK, EU member states, and EFTA countries (Iceland, Liechtenstein, Norway). Regulatory approvals span 33 countries including US (April 2024), UK (July 2025), EU (February 2026), and Saudi Arabia (January 2026). ANKTIVA represents ImmunityBio's first global approval for combination use with checkpoint inhibitors in metastatic lung cancer.
• Biopharma & Cigalah HealthcarecoreChannel Partner/ Reseller/ Distributor · 1 February 2026Accord Healthcare partnered with Biopharma & Cigalah Healthcare for distribution of ANKTIVA in Saudi Arabia and the broader Middle East and North Africa (MENA) region, complementing the European distribution partnership with ImmunityBio.
• Kashiv BioSciencescoreStrategic or Co-development Partner · 1 February 2026Kashiv BioSciences signed an exclusive licensing and supply agreement with Intas Pharmaceuticals (Accord's parent company) for a complex peptide product covering European, UK, and Indian markets. Under the agreement, Kashiv handles regulatory registration, manufacturing, and supply while Accord Healthcare manages commercialization and distribution across all regions. The partnership enables Kashiv to expand into major markets using Intas's established European presence.
• Prothya Biosolutions Belgium BVcoreStrategic or Co-development Partner · 1 October 2025Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries to expand Accord's plasma therapy capabilities. Prothya is a plasma-derived medicinal products (PDMP) business primarily based in the Netherlands and Belgium. The acquisition strengthens Accord's presence in blood plasma business and expands access to plasma-derived medicines worldwide.

Scale indicators22 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Polpharma: Polish generics and APIs manufacturer with Central European heritage, hospital and OTC portfolio. Comparable to Accord in generic pharma manufacturing and CEE/Western European commercialization.
• Viatris: Mylan-Upjohn combined entity; one of the largest global generics manufacturers with established European commercial infrastructure, hospital channel presence and biosimilars portfolio. Direct overlap with Accord's generics, biosimilars and European footprint.
• Krka: Slovenian generics manufacturer with strong Central and Eastern European presence across prescription generics, OTC, and animal health. Comparable to Accord in generics focus, CEE/Western Europe footprint, and in-house manufacturing.
• Sandoz: Novartis's generics and biosimilars spinoff; the largest European-based generics manufacturer with global reach across prescription generics and biosimilars. Closest direct comparable to Accord's generic + biosimilar strategy and European footprint.
• Stada Arzneimittel: German-based European generics and specialty pharma company with a broad hospital and retail pharmacy portfolio including biosimilars. Highly comparable to Accord in portfolio breadth, geographic focus on Europe and emphasis on specialty generics.
• Teva Pharmaceutical Industries: Global generics and specialty pharma major with a heavy European presence, broad generic portfolio and growing biosimilars pipeline. Comparable in scale to Accord across generics, biosimilars, and CNS/autoimmune franchises.
• Zentiva: European-focused generics manufacturer with significant hospital and retail pharmacy presence across CEE and Western Europe; recently expanded through Bain Capital ownership. Direct comparable in European generics strategy.

Regional players

• Glenmark Pharmaceuticals: India-headquartered global generics and specialty pharma company with a substantial European operations and a portfolio spanning generics, biosimilars and specialty. Comparable to Accord in origin (India-headquartered), generics focus and European expansion.

Emerging players

• Celltrion: Korean biosimilars leader with multiple EU-approved biosimilars (infliximab, rituximab, trastuzumab, etc.) and growing European commercial reach. Direct competitor to Accord's biosimilar growth ambitions.
• Alvotech: Iceland-headquartered biosimilars pure-play with EU-approved biosimilars and a manufacturing platform focused on complex biologics. Comparable to Accord's biosimilars franchise and competitive in the autoimmune/oncology biosimilar space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/accord-healthcare

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Accord Healthcare